A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation

Stopped PI was away on sabbatical for 2 years.Protocol is being revised before starting the study.

Conditions

• Oral Mucositis in Patients Undergoing HSCT

Interventions

• DRUG: Lactobacillus CD 2
• OTHER: Placebo

Sponsor

All India Institute of Medical Sciences